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Although alterations in adenylate cyclase (AC) activity
and somatostatin (SRIF) receptor density have been
reported in Alzheimer’s disease, the effects of amyloid
b-peptide (Ab) on these parameters in the hippocam-
pus are unknown. Our aim was to investigate whether
the peptide fragment Ab(25–35) can affect the soma-
tostatinergic system in the rat hippocampus. Hence,
Ab(25–35) was injected intracerebroventricularly (i.c.v.)
to Wistar rats in a single dose or infused via an osmotic
minipump connected to a cannula implanted in the
right lateral ventricle during 14 days. The animals were
decapitated 7 or 14 days after the single injection and
14 days after chronic infusion of the peptide. Chronic
i.c.v. infusion of Ab(25–35) decreased SRIF-like immu-
noreactive content without modifying the SRIF receptor
density, SRIF receptor expression, or the Gia1, Gia2,
and Gia3 protein levels in the hippocampus. This treat-
ment, however, caused a decrease in basal and forsko-
lin-stimulated AC activity as well as in the capacity of
SRIF to inhibit AC activity. Furthermore, the protein
levels of the neural-speciﬁc AC type I were signiﬁcantly
decreased in the hippocampus of the treated rats,
whereas an increase in the levels of AC V/VI was found,
with no alterations in type VIII AC. A single i.c.v. dose
of Ab(25–35) exerted no effect on SRIF content or SRIF
receptors but induced a slight decrease in forskolin-
stimulated AC activity and its inhibition by SRIF. Be-
cause chronic Ab(25–35) infusion impairs learning and
memory whereas SRIF facilitates these functions, the
alterations described here might be physiologically im-
portant given the decreased cognitive behavior previ-
ously reported in Ab-treated rats. VC 2006 Wiley-Liss, Inc.
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The neuropeptide somatostatin-14 (SRIF-14) is a cy-
clic tetradecapeptide, which is widely distributed in the
peripheral and central nervous systems (Epelbaum, 1986).
In the hippocampus, immunohistochemical studies have
revealed many SRIF-containing interneurons and a pro-
fuse network of intrinsic and extrinsic SRIF-containing
ﬁbers that appears to project to pyramidal and granule
neurons (Bakst et al., 1986; Jo¨els et al., 1990). Behavioral
and clinical ﬁndings suggest an important role for SRIF
in cognitive functions (Epelbaum, 1986). Speciﬁc SRIF
receptors are present in the hippocampus (Reubi and
Maurer, 1985), suggesting that SRIF may be a neuro-
transmitter or neuromodulator in the hippocampal for-
mation. The actions of SRIF are mediated by speciﬁc
high-afﬁnity, membrane receptors, which are sensitive to
guanine nucleotides. Five SRIF receptor subtypes, termed
sst1–sst5, have thus far been cloned (Bell and Reisine,
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1993). These receptors are expressed in different amounts
in the CA1 region of the hippocampus (Csaba and Dour-
naud, 2001) and are negatively coupled to adenylate cy-
clase (AC) via inhibitory guanine nucleotide-binding pro-
teins (Gi proteins). Among the numerous neuropeptides
produced in intrinsic hippocampal and cortical neurons,
SRIF has been found to be the most consistently reduced
in Alzheimer’s disease (AD) (Davies et al., 1980; Rossor
et al., 1980; Wood et al., 1982; Reinikainen et al., 1987;
Atack et al., 1988).
AD is an irreversible neurodegenerative disorder
that is characterized clinically by progressive dementia
and histopathologically by the presence of extracellular
deposits of amyloid ﬁbrils in the core of senile plaques,
intracellular neuroﬁbrillar tangles, and neuronal cell loss
(Braak and Braak, 1991). One of the principal compo-
nents of senile plaques, amyloid b-peptide (Ab), is con-
sidered to be involved in the pathogenesis of AD (Hsiao
et al., 1996; Selkoe, 2001). An accumulation of Ab has
been associated with progressive neuronal death, cogni-
tive deﬁcits, and neuropsychiatric disorders such as agita-
tion, apathy, and increased anxiety (Hardy and Higgins,
1992; Selkoe, 1996; Weiner et al., 1997; Sheuner et al.,
2004; Stepanichev et al., 2004). Recent studies suggest
that neurotransmitter receptor function in AD may be
compromised because of disrupted postreceptor signal
transduction, in particular, the phosphoinositide and AC
pathways (Cowburn et al., 2001). AC activity has been
reported to be reduced in different brain regions of
patients with AD (Ohm et al., 1991; Cowburn et al.,
1992; Ross et al., 1993). Ohm et al. (1991) observed a
signiﬁcant reduction in basal and stimulated AC activity
in the AD hippocampus, a brain area that typically shows
severe histopathological changes in this disorder. No
signiﬁcant changes in the levels of any of the G-proteins,
however, were detected in the AD frontal cortex or hip-
pocampus (Ross et al., 1993). Bergstro¨m et al. (1991)
reported a reduction in the inhibitory effect of SRIF on
AC activity in the superior temporal cortex of a group
of AD cases compared with a group of matched con-
trols, with no changes in other brain regions. Studies on
the SRIF receptor binding sites in the AD brain have
given conﬂicting results (Beal et al., 1985; Cowburn
et al., 1991). It is presently unknown, however, whether
Ab can alter the inhibitory effect of SRIF on AC activ-
ity in the rat hippocampus.
In view of these facts, we sought to determine
whether Ab(25–35), an 11-amino-acid fragment of Ab,
can affect the rat hippocampal somatostatinergic system.
Hence, we measured basal and forskolin (FK)-stimulated
AC activity, the capacity of SRIF to inhibit both activ-
ities, and the protein levels of the AC isoforms I, V/VI
and VIII in rat hippocampal membranes. We also tested
whether Ab(25–35) can alter the binding of SRIF to its
receptors, the expression of the SRIF receptor subtypes
sst1–sst4, the SRIF-like immunoreactive (SRIF-LI) con-
tent, or Gia1, Gia2, or Gia3 protein levels in the rat
hippocampus after either acute or chronic intracerebro-
ventricular (i.c.v.) administration. The hippocampus was
chosen for this study because of its involvement in cog-
nitive functions (Kesner and Hopkins, 2006), in which
SRIF plays a pivotal role.
MATERIALS AND METHODS
Chemicals
Synthetic Tyr11-SRIF and SRIF-14 were purchased from
Universal Biologicals Ltd. (Cambridge, United Kingdom).
Ab(25–35), Ab(35–25), bacitracin, phenylmethylsulfonyl ﬂuo-
ride (PMSF), 3-isobutyl-1-methylxanthine (IBMX), bovine
serum albumin (fraction V; BSA), guanosine triphosphate
(GTP), and forskolin (FK) were purchased from Sigma (Madrid,
Spain). Speciﬁc antisera against the ai1 (MAB3075) or ai2
(MAB3077) G protein subunits were obtained from Chemi-
con International (Temecula, CA). Speciﬁc antisera against
the G protein subunit ai3 (sc-262), the AC isoforms AC I
(sc-25743), AC V/VI (sc-590), and AC VIII (sc-1967), the
somatostatin receptor subtypes sst1 (sc-11604), sst2 (sc-11606),
sst3 (sc-11614), and sst4 (sc-11619), and the secondary anti-
body (mouse IgG-peroxidase conjugate) were obtained from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). The nitro-
cellulose membranes and the chemiluminescence Western
blotting detection system were purchased from Amersham
(Buckinghamshire, United Kingdom). Dextran was obtained
from Serva Feinbiochemica (Heidelberg, Germany) and car-
rier-free Na125I (IMS 30; 100 mCi/ml) from the Radiochem-
ical Centre (Amersham). The rabbit antibody used in the radi-
oimmunoassay technique was purchased from the Radiochem-
ical Centre (Amersham). This antiserum was raised in rabbits
against SRIF-14 conjugated to BSA and is speciﬁc for SRIF,
but, because SRIF-14 constitutes the C-terminal portions of
both SRIF-25 and SRIF-28, the antiserum does not distin-
guish among these three forms.
Experimental Animals
All procedures conform to the guidelines set by our Ani-
mal Care and Use Committee and were approved by this com-
mittee before implementation. All efforts were made to mini-
mize animal suffering and to use only the number of animals
necessary to produce reliable scientiﬁc data. Thirty male Wistar
rats weighing 200–250 g were used in this study. All animals
received food and tap water ad libitum. Room temperature
was kept at 228C, and a 12-hr day-night cycle was maintained.
Ab(25–35) was dissolved in 1% acetic acid according to the
manufacturer’s instructions and was incubated at 378C on the
day before its administration. Ab(25–35) was administered i.c.v.
to the rats in a single dose (10 lg) or via an osmotic minipump
(Alzet) connected to a cannula implanted in the rat right lateral
ventricle, as previously described (Nitta et al., 1994; Ping Tang
et al., 2000; Fukuta et al., 2001; Nag and Tang, 2001). Chronic
Ab(25–35) or Ab(35–25) infusion was carried out at a dose of
300 pmol/day for 14 days (Nag and Tang, 2001). Control ani-
mals received equivalent volumes of the vehicle, 1% acetic acid,
to control whether acetic acid per se could lead to pathogenic
changes. The animals were decapitated 7 or 14 days after the
single injection of Ab(25–35) and 14 days after chronic infu-
sion of the peptide. The brains were quickly removed from the
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skull, and the hippocampus was immediately dissected over ice
as described by Glowinski and Iversen (1966).
Tissue Extraction and Somatostatin Radioimmunoassay
For measurements of SRIF-LI content, the hippocam-
pus was homogenized in 1 ml of 2 M acetic acid using a
Brinkman polytron (setting 5, 30s). Extracts were boiled for
5 min in a water bath and chilled in ice. Subsequently, ho-
mogenates were centrifuged at 15,000g for 15 min at 48C.
The pellet was discarded, and 25 ll of the supernatant was
taken for determination of protein concentration (Lowry
et al., 1951). The extracts were immediately stored at –808C
until the time of assay. The SRIF-LI content was determined
in tissue extracts by a modiﬁed radioimmunoassay method
(Patel and Reichlin, 1978). Brieﬂy, the assay tubes contained
100 ll of unknown or standard solutions (0–500 pg) of cyclic
SRIF-14, diluted in 0.1 M phosphate buffer, pH 7.2, contain-
ing 0.2% BSA and 0.1% sodium azide, 200 ll of appropriately
diluted anti-SRIF serum, 100 ll of freshly prepared 125I-
Tyr11-SRIF, diluted in buffer to yield 6,000–10,000 cpm
(equivalent to 5–10 pg) and enough buffer to give a ﬁnal
volume of 0.8 ml. All reagents, as well as the assay tubes,
were kept chilled in ice before their incubation at 48C for
24 hr. The separation of bound and free hormone was accom-
plished by addition of 1 ml dextran-coated charcoal (dextran:
0.2% w/v). The coefﬁcients for intra- and interassay variation
were 6.3% and 8.1%, respectively.
Binding Assay
Tyr11-SRIF was radioiodinated by the chloramine-T
method according to Greenwood et al. (1963). The tracer was
puriﬁed in a Sephadex G-25 ﬁne column (1 3 100 cm) equi-
librated with 0.1 M acetic acid containing BSA 0.1% (w/v).
The speciﬁc activity of the puriﬁed labeled peptide was about
600 Ci/mmol. Hippocampal membranes were prepared as
previously described by Reubi et al. (1981). The protein con-
centration was assayed by the method of Lowry et al. (1951),
with BSA as a standard. Speciﬁc SRIF binding was measured
according to the modiﬁed method of Czernik and Petrack
(1983). Brieﬂy, the membranes (0.15 mg protein/ml) were
incubated in 250 ll of a medium containing 50 mM Tris-
HCl buffer (pH 7.5), 5 mM MgCl2, 0.2% (w/v) BSA and
0.1 mg/ml bacitracin with 250 pM of 125I-Tyr11-SRIF either
in the absence or in the presence of 0.01–10 nM unlabelled
SRIF. After a 60 min incubation at 308C, the bound and free
ligand were separated by centrifugation at 11,000g for 2 min,
and the radioactivity in the resultant pellet was measured.
Nonspeciﬁc binding was obtained from the amount of radio-
activity bound in the presence of 10–7 M SRIF and repre-
sented about 20% of the binding observed in the absence of
unlabelled peptide. This nonspeciﬁc component was sub-
tracted from the total bound radioactivity to obtain the corre-
sponding speciﬁc binding.
Evaluation of Radiolabeled Peptide Degradation
The inactivation of 125I-Tyr11-SRIF in the incubation
medium after exposure to membranes was studied by mea-
suring the ability of the preincubated peptide to rebind to
fresh membranes (Aguilera et al., 1982). Brieﬂy, 125I-Tyr11-
SRIF (250 pM) was incubated with rat hippocampal mem-
branes (0.15 mg protein/ml) for 60 min at 308C. After this
preincubation, aliquots of the medium were added to fresh
membranes and incubated for an additional 60 min at 308C.
The fraction of the added radiolabeled peptide that was specif-
ically bound during the second incubation was measured and
expressed as a percentage of the binding that had been ob-
tained in control experiments performed in the absence of
membranes during the preincubation period.
AC Assay
AC activity was measured as previously reported (Houslay
et al., 1976), with minor modiﬁcations. Brieﬂy, hippocampal
membranes (0.06 mg/ml) were incubated with 1.5 mM ATP,
5 mM MgSO4, 10 lM GTP, an ATP-regenerating system
(7.5 mg/ml creatine phosphate and 1 mg/ml creatine kinase),
1 mM IBMX, 0.1 mM PMSF, 1 mg/ml bacitracin, 1 mM
EDTA, and test substances (10–4 M SRIF or 10–5 M FK) in
0.1 ml of 0.025 M triethanolamine/HCl buffer (pH 7.4). After
a 15-min incubation at 308C, the reaction was stopped by
heating the mixture for 3 min. After cooling, 0.2 ml of an
alumina slurry (0.75 g/ml in triethanolamine/HCl buffer, pH
7.4) was added, and the suspension was centrifuged. The super-
natant was taken for assay of cAMP by the method of Gilman
(1970).
Immunodetection of ai Subunits of G Proteins,
AC Isoforms, and SRIF Receptor Subtypes
Membranes (100 lg) were solubilized in SDS-sample
buffer. The proteins were then run on a 12% SDS-polyacryl-
amide gel, as described by Laemmli (1970). After separation, the
proteins were transferred onto nitrocellulose membranes in a
buffer consisting of 25 mM Tris/HCl, pH 8.3, 192 mM glycine,
20% methanol, and 0.05% SDS. The nitrocellulose membranes
were then blocked with TTBS (50 mM Tris/HCl, pH 7.5,
150 mM NaCl, and 0.05% Tween-20) containing 5% (w/v)
nonfat dry milk for 1.5 hr at 48C. The nitrocellulose membranes
were subsequently incubated with the corresponding antibodies:
mouse anti-Gia1 or anti-Gia2 monoclonal antibody (1:1,000
dilution), rabbit anti-Gia3 polyclonal antibody (1:1,000 dilution),
rabbit anti-AC I, AC V/VI, or AC VIII polyclonal antibody
(1:1,000 dilution) or goat anti-sst1, anti-sst2, anti-sst3, or anti-sst4
polyclonal antibody (1:1,000 dilution) in TTBS overnight at 48C.
After incubation, three 5-minwashes in TTBS containing 5% (w/v)
nonfat dry milk were carried out. A goat or mouse IgG-
peroxidase conjugate (1:2,000 dilution) in TTBS was then added
to the membranes and incubated for 1 hr at 48C. After washing,
the bound immunoreactive proteins were detected by a chemilu-
minescent (ECL) Western blotting detection system. Quantiﬁca-
tion of the bands was carried out by densitometric analysis in
Scion Image (Scion Inc.).
Data Analysis
The computer program Ligand (Munson and Rodbard,
1980) was used to analyze the binding data. The use of this
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program allows models of receptors that best ﬁt a given set of
binding data to be selected. The same program was also used
to present data in the form of Scatchard plots (1949) and to
compute values for receptor afﬁnity (Kd) and density (Bmax)
that best ﬁt the sets of binding data for each rat. Statistical
comparisons of all data were carried out by one-way analysis
of variance (ANOVA) and the Student-Newman-Keuls test.
Means among groups were considered signiﬁcantly different
when the P values were less than 0.05. Each individual
experiment was performed in duplicate.
RESULTS
SRIF-Like-Immunoreactive Content
Is Reduced in Ab(25–35)-Treated Rats
Chronic i.c.v. infusion of Ab(25–35) during 14
days induced a signiﬁcant decrease in SRIF-LI content
in the rat hippocampus compared with controls (Fig. 1).
Effect of Ab(25–35) on Hippocampal
SRIF Receptors
Hippocampal membranes from control and Ab(25–
35)-treated rats bound 125I-Tyr11-SRIF in a time-depen-
dent manner, an apparent equilibrium being observed
between 50 and 180 min at 308C. All subsequent experi-
ments were therefore conducted at 308C for 60 min.
The results show a lack of effect of Ab(25–35) or
the reverse Ab(35–25) on SRIF binding to its receptors
in rat hippocampal membranes (Table I) following either
a single i.c.v. administration or chronic infusion of the
peptide. Hippocampal membranes from control and
Ab(25–35)-treated rats showed a similar tracer degrada-
tion capacity, the values varying by no more than 10% in
all the experimental groups. Because the tracer used in
the binding assay, Tyr11-SRIF-14, binds with similar af-
ﬁnity to all the SRIF receptor subtypes, we next analyzed
the expression of sst1, sst2, sst3, and sst4 to evaluate the
possibility that one of these subtypes is altered. Western
blot analyses with subtype-speciﬁc antibodies revealed no
alterations in the protein levels of any of these receptors
in hippocampal membranes from rats treated chronically
with Ab(25–35) compared with control rats (Fig. 2).
Reduction of AC Activity and AC I
Levels by Ab(25–35)
We next sought to examine some of the compo-
nents of the SRIF signalling pathway in control and
Ab(25–35)-treated rats. Because SRIF receptors are neg-
atively coupled to the effector AC, we measured basal
and FK-stimulated AC activity as well as SRIF-mediated
inhibition of the enzyme in hippocampal membranes
Fig. 1. Effect of chronic (14 days) i.c.v. infusion of Ab(25–35) on
somatostatin-like immunoreactivity (SRIF-LI) concentration in the
rat hippocampus. Open bars correspond to control rats and solid bars
to Ab(25–35)-treated rats. Results are expressed as the mean 6 SEM
of ﬁve rats in each group. Statistical comparisons of the data were
carried out by one-way ANOVA and Student’s Newman-Keuls test.
Statistical signiﬁcance vs. control: *P < 0.05.
TABLE I. Equilibrium Parameters for 125I-Tyr11-Somatostatin
(125I-Tyr11-SRIF) Binding to Hippocampal Membranes From
Control Rats, Rats Treated With a Single i.c.v. Dose of
Ab(25–35) (10 mg) at 7 or 14 Days of Administration and Rats
Treated for 14 Days With Ab(25–35) (300 pmol/day) or
Ab(35–25) (300 pmol/day)*
Groups
Somatostatin receptors
Bmax Kd
Control 537 6 6 0.52 6 0.03
Ab(25–35) (single dose, 7 days) 472 6 31 0.54 6 0.04
Control 415 6 40 0.53 6 0.04
Ab(25–35) (single dose, 14 days) 476 6 36 0.58 6 0.06
Control 523 6 22 0.51 6 0.03
Ab(25–35) (chronic infusion, 14 days) 492 6 27 0.50 6 0.05
Ab(35–25) (chronic infusion, 14 days) 440 6 37 0.46 6 0.02
*Binding parameters were calculated from Scatchard plots by linear
regression. Units for Kd are nM, and units for Bmax are fmoles SRIF
bound/mg protein. The results are represented as the mean 6 SEM of
ﬁve separate experiments, each performed in duplicate.
Fig. 2. Effect of chronic (14 days) i.c.v. infusion of Ab(25–35) on
protein levels of the somatostatin receptor subtypes sst1–sst4. Hippo-
campal membranes from control and Ab(25–35)-treated rats were
resolved by SDS-PAGE as described in Materials and Methods. Pro-
teins were transferred to nitrocellulose membranes, and the immuno-
detection was achieved using a goat anti-sst1, anti-sst2, anti-sst3, or
anti-sst4 polyclonal antibody. In each case, b-tubulin was used as a
loading control. Each experiment is representative of ﬁve others.
Lanes 1, 3, and 5 correspond to control rats; lanes 2, 4, and 6 corre-
spond to Ab(25–35)-treated rats.
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from control and Ab(25–35)-treated rats. As shown in
Figure 3, chronic infusion of Ab(25–35) during 14 days
caused a decrease in both basal and FK-stimulated AC
activity. Although basal and FK-stimulated AC activities
were inhibited by SRIF in all the experimental groups
studied, the capacity of SRIF to inhibit FK-stimulated
AC activity was signiﬁcantly lower in the rats treat-
ed chronically with Ab(25–35) compared with controls
(Fig. 3). No signiﬁcant differences in basal and FK-
stimulated AC activity or in SRIF-induced inhibition of
these activities were detected in the hippocampal mem-
branes of rats treated acutely with a single dose of
Ab(25–35) at 7 days of administration (Table II). There
was a slight decrease, however, in FK-stimulated AC
activity and its inhibition by SRIF at 14 days of adminis-
tration (Table II). These results led us to investigate
further the cause of the reduction observed after chronic
infusion of the peptide. We therefore analyzed the
expression of the AC isoforms AC I, AC V/VI, and AC
VIII at the protein level by means of Western blot.
Type I and type VIII AC are Ca2+/calmodulin-sensitive
enzymes that are expressed exclusively in brain. AC V
and VI, present in brain and heart, are two isoforms that
are sensitive to inhibition by Gi proteins, including
Gia1, Gia2, and Gia3. Representative immunoblots of
these AC isoforms are shown in Figure 4. The results
revealed a signiﬁcant decrease in the protein levels of
type I AC, whereas an increase in AC V/VI levels was
found in the Ab-treated group compared with the
control group (Fig. 4). No differences in type VIII AC
Fig. 3. Effect of chronic i.c.v. infusion of Ab(25–35) (300 pmol/
day) during 14 days on basal and forskolin (FK; 10–5 M)-stimu-
lated adenylate cyclase (AC) activity as well as on somatostatin
(SRIF)-mediated inhibition of AC activity in rat hippocampal
membranes. Membrane preparations from control (open bars) or
Ab(25–35)-treated rats (solid bars) were incubated with or without
SRIF (10–4 M) in the absence (basal) or presence of 10–5 M FK.
Data are expressed as the mean 6 SEM of ﬁve rats. Each experi-
ment was performed in duplicate. Statistical comparison vs. the
control group: *P < 0.05. Inset: Percentage of SRIF-mediated
inhibition of basal or stimulated (+FK) AC activity. Statistical
comparison vs. the control group: **P < 0.01.
TABLE II. Effect of Somatostatin (SRIF; 104 M) and Forskolin (FK; 105 M) on Adenylyl Cyclase Activity (pmol cAMP/min/mg
Protein) in Hippocampal Membranes From Control Rats (n ¼ 5) and Rats Treated With a Single Dose (10 mg) of Ab(25–35) (n 5 5)
at 7 or 14 Days of Administration{
Control Ab(25–35) (7 days) Control Ab(25–35) (14 days)
Basal activity 332 6 22 304 6 38 267 6 27 253 6 35
+104 M SRIF 236 6 14 212 6 31 189 6 10 173 6 7
SRIF inhibition of basal activity (%) 28.6 6 0.8 31.6 6 3.3 30.4 6 2.1 30.3 6 3.2
+105 M FK 851 6 63 818 6 75 889 6 28 796 6 24*
+105 M FK + 104 M SRIF 591 6 75 563 6 38 589 6 68 574 6 44
SRIF inhibition of FK-stimulated activity (%) 30.8 6 2.3 29.3 6 7 32.2 6 1.6 27.9 6 1.1**
-Fold FK stimulation 2.6 6 0.3 2.7 6 0.4 3.2 6 0.3 3.1 6 0.4
{Data are the mean 6 SEM of ﬁve separate experiments, each performed in duplicate.
*P < 0.05 vs. control.
**P < 0.01 vs. control.
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content, however, were detected among these experi-
mental groups.
Gia Protein Levels Are Unaltered in Hippocampal
Membranes From Ab(25–35)-Treated Rats
The inhibitory G proteins Gia1, Gia2, and Gia3
all mediate the effects of SRIF signals on AC. Hence,
our next objective was to determine whether the levels
of the a subunits of these proteins were affected by
Ab(25–35). Western blot analyses revealed that chronic
i.c.v. infusion of Ab(25–35) during 14 days does not
signiﬁcantly modify ai1, ai2, or ai3 protein levels in
rat hippocampal membranes compared with controls
(Fig. 5). Likewise, a single dose of Ab(25–35) exerted
Fig. 5. Right: Immunodetection of the ai1, ai2, and ai3 subunits of
G proteins. Hippocampal membranes from control and Ab(25–35)-
treated rats were resolved by SDS-PAGE as described in Materials
and Methods. Proteins were transferred to nitrocellulose membranes,
and the immunodetection was achieved by using mouse anti-Gia1 or
anti-Gia2 monoclonal antibodies or an anti-Gia3 polyclonal anti-
body. Lanes 1 and 3 correspond to control rats; lanes 2 and 4 corre-
spond to Ab(25–35)-treated rats. Each experiment is representative
of ﬁve others. For details see Materials and Methods. Left: Densito-
metric analysis of the bands obtained. Integrated optical densities for
control bands were assigned an arbitrary value of 100. Integrated
optical densities for bands corresponding to chronic infusion of
Ab(25–35) are presented as a percentage of the control value. Data
represent the mean 6 SEM.
Fig. 4. Effect of chronic i.c.v. infusion of Ab(25–35) during 14 days
on the protein levels of the adenylate cyclase isoforms AC I, AC
V/VI, and AC VIII in the rat hippocampus. Hippocampal mem-
branes from control and Ab(25–35)-treated rats were resolved on
SDS-PAGE as described in Materials and Methods. Top: Proteins
were transferred to nitrocellulose membranes, and the immunodetec-
tion was achieved by using a rabbit anti-AC I (A), anti-AC VIII (A),
or anti-AC V/VI (B) polyclonal antibody. Lanes 1, 3, and 5 corre-
spond to control rats; lanes 2, 4, and 6 correspond to Ab(25–35)-
treated rats. In each case, b-tubulin was used as a loading control.
Each experiment is representative of ﬁve others. For details see Mate-
rials and Methods. Bottom: Densitometric analysis of the bands
obtained in the immunoblots corresponding to AC I (A) or AC
V/VI (B). Integrated optical densities for bands were assigned an
arbitrary value of 100. Integrated optical densities for bands corre-
sponding to chronic infusion of Ab(25–35) are represented as a
percentage of the control value. Data represent the mean 6 SEM.
Statistical comparison vs. control: *P < 0.05, **P < 0.01.
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no effect on this parameter at 7 or 14 days of injection
(data not shown).
DISCUSSION
In this study we have used an 11-amino-acid frag-
ment of the Ab peptide, Ab(25–35), which is located at
the C-terminal end of Ab(1–42) in the hydrophobic
domain. Recent studies carried out by Kubo et al.
(2002) reinforce the hypothesis that soluble (D-Ser26)
Ab(1–40), possibly produced during aging, is released
from plaques and converted by proteolysis to toxic
(D-Ser26)-Ab(25–35/40), which damages hippocampal
CA1 neurons by enhancing excitotoxicity in AD. By
using speciﬁc anti-(D-Ser26)-Ab(25/26–35/40) antibod-
ies, Kubo et al. (2002) demonstrated clearly that the
truncated fragments (D-Ser26 )-Ab(25/26–35/40) were
present in the brains of AD patients, but not in the age-
matched control subjects.
The experimental paradigm, i.c.v. infusion of Ab
(25–35), has been demonstrated by several authors rele-
vantly to mimic some of the pathological processes in
AD brain. A large body of experimental data has dem-
onstrated that Ab injected i.c.v. to rodents signiﬁcantly
inﬂuences their cognitive behavior. The peptide frag-
ment Ab(25–35), in particular, has been demonstrated to
induce impairment of spontaneous alternation behavior
(Stepanichev et al., 2000), water maze and radial maze
learning (Yamaguchi and Kawashima, 2001; Sun and
Alkon, 2002), passive avoidance (Yamaguchi and Kawa-
shima, 2001), and social recognition (Stepanichev et al.,
2000) in rats. In addition, damaged cells and neuronal
loss in the hippocampal subﬁelds CA1 and CA3 as well
as in the neocortex and basal ganglia were observed after
i.c.v. administration of Ab(25–35) to aged rats (Stepani-
chev et al., 2000).
The effects of Ab(25–35) on different components
of the SRIF signalling pathway in the rat hippocampus
were more pronounced after chronic infusion than after
a single administration of the peptide, even though the
dose administered acutely was slightly higher. Dornan
et al. (1993) failed to show any focal deposit of Ab(25–
35) in the rat hippocampus when the peptide was
administered acutely. Studies by Nag et al. (1999), how-
ever, have revealed a clear and widespread presence of
Ab immunoreactivity in rats that received a chronic
i.c.v. infusion of Ab during 14 days, achieving a ﬁnal
concentration of 4.2 nmol, the same as that used in our
study. Furthermore, there was abundant Ab immuno-
reactivity in the hippocampal formation. Thus, the tem-
poral feature observed in our study implies a chronic
pathological process in the hippocampus triggered by the
gradual accumulation of Ab(25–35).
The SRIF-LI content in the hippocampus of con-
trol rats was similar to that previously reported by our
group (Puebla and Arrila-Ferreiro, 2003) and by others
(Srikant and Patel, 1981). The present study demon-
strates that chronic i.c.v. infusion of Ab(25–35) leads to
a reduction in hippocampal SRIF-LI levels. Notably, the
alteration in SRIF content demonstrated here parallels
that seen in brains of AD patients (Davies et al., 1980;
Slama et al., 1991). To date, however, it is unknown
whether these changes are caused directly by the toxic
effect of Ab(25–35). There is evidence suggesting that
Ab(25–35) induces the opening of mitochondrial pores,
which is an important aspect in the mechanism of neu-
rotoxicity (Bachurin et al., 2003). The changes in SRIF-
LI content observed might also be, to a certain extent,
secondary to the cholinergic dysfunction demonstrated
in AD and in Ab protein-infused rats (Itoh et al., 1996).
Alternatively, Ab(1–42) has been reported to im-
pair cAMP response element binding protein (CREB)
signalling in neurons (Tong et al., 2001). It is well estab-
lished that the gene encoding for SRIF contains a
cAMP response element designated CRE (Montminy
and Bilezikjian, 1987). The second messenger cAMP can
induce transcription of the SRIF gene via PKA-induced
phosphorylation of the protein CREB, which is a tran-
scription factor that subsequently binds to CRE (Mont-
miny and Bilezikjian, 1987). Hence, a decrease in SRIF
gene expression resulting from decreased CREB signal-
ling might explain, partially or wholly, the decrease in
hippocampal SRIF content observed in our study.
Chronic i.c.v. infusion of Ab(25–35) reduced basal
and FK-stimulated AC activity in the rat hippocampal
membranes. This ﬁnding is in line with a post-mortem
study carried out by Ohm et al. (1991), which showed
reduced FK-stimulated enzyme activities in the AD
hippocampus. This suggested a loss of AC enzyme units
in AD, which has been supported by more recent im-
munoblotting studies using isoform-speciﬁc antibodies.
Molecular cloning techniques have thus far identiﬁed
nine mammalian genes that encode membrane-bound
ACs and one gene encoding a soluble isoform (Sunahara
and Taussig, 2002). In our study, we focused on four
AC isoforms, namely, AC I, AC V/VI, and AC VIII.
Types I and VIII, which are expressed exclusively in the
brain, have been postulated to play a pivotal role in
learning and memory. The results obtained demonstrate
a selective reduction in the protein levels of AC I as a
result of chronic Ab(25–35) infusion in the rat hippo-
campus. These results are partially concordant with stud-
ies by Yamamoto et al., who showed a signiﬁcant loss of
AC type I in the AD hippocampus (Yamamoto et al.,
2000) and AD parietal cortex (Yamamoto et al., 1996,
1997). The decrease we observe might in part explain
the attenuation of AC activity under both basal and
stimulated conditions in the Ab(25–35)-treated rats. Fur-
thermore, it is plausible that this reduction might con-
tribute to a decreased phosphorylation of CREB in
somatostatinergic neurons, which in turn would lead to
the decrease in the rat hippocampal SRIF-LI content.
This is feasible given the fact that SRIF is also involved
in cognitive processes. Type VIII AC, on the other
hand, was unaffected by chronic Ab(25–35) infusion, in
contrast to human AD hippocampus, in which a
decrease was found (Yamamoto et al., 2000). We also
tested AC V/VI, both of which are abundant in heart
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and brain. SRIF receptors couple negatively to AC via
the inhibitory G proteins Gia1, Gia2, and Gia3, which
have all been demonstrated to inhibit these two AC
isoforms selectively (Sunahara and Taussig, 2002). Inter-
estingly, an increase in AC V/VI protein levels was
detected in the hippocampal membranes derived from
rats treated chronically with Ab. Although the functional
signiﬁcance of this increase is as yet unknown, it does
seem to argue against the possibility that the lower
expression of AC I in the Ab(25–35)-treated group
might be due to a loss of neurons, taking into account
that damaged cells and neuronal loss have been reported
in the hippocampal subﬁelds CA1 and CA3 of AD
patients; if this were the case, all isoforms studied would
be decreased.
The levels of the a subunits of the Gi proteins
were not signiﬁcantly altered after either acute or
chronic i.c.v. administration of Ab(25–35). However,
preservation of G protein levels is not necessarily indica-
tive of the integrity of signal transduction in the disease
state. Thus, whereas the numbers of SRIF receptors are
unaltered in the present study as well as in the AD
hippocampus, the ability of SRIF to inhibit AC is
reduced. This result is in agreement with that obtained
by Cowburn et al. (1991) in the temporal cortex of AD
patients. The loss of AC activity, therefore, cannot be
attributed to an altered Gi expression.
Although the underlying mechanism for the
Ab(25–35)-induced effects is not fully understood, it
might be related to the ability of Ab(25–35) to initiate
membrane lipid peroxidation and to enhance oxidative
stress (Mark et al., 1997; Stepanichev et al., 2004). In
this regard, it has been demonstrated that direct infusion
of Ab peptides into rat brain leads to a signiﬁcant
increase in the production of reactive oxygen species
(Parks et al., 2001; Stepanichev et al., 2004). Further-
more, Ab(25–35) administration has been reported to
lead to a gradually developing oxidative stress in the rat
hippocampus.
Our results indicate that there are no signiﬁcant
changes in the SRIF binding capacity in the hippocam-
pus of rats infused with Ab(25–35) compared with con-
trols. This result is in agreement with some (Whitford
et al., 1988; Slama et al., 1991) but not all (Beal et al.,
1985) studies carried out in the AD hippocampus. Slama
et al. (1991) observed no signiﬁcant changes in the total
SRIF binding capacity in the hippocampus of patients
with dementia compared with controls. Because the
SRIF analog used in the binding assay, however, has
afﬁnity for all ﬁve SRIF receptor subtypes, we measured
the protein levels of each subtype except for sst5, owing
to its very low expression in the rat hippocampus.
Western blot analysis revealed no differences in sst1–sst4
protein levels between the control and the Ab(25–35)-
treated rats, which agrees with the binding data. Thus,
the possibility that the reduction of AC activity is due to
a decreased sst density can be discarded.
Together, the present data demonstrate that, al-
though the hippocampal SRIF receptors are fairly well
preserved after chronic Ab(25–35) infusion, their func-
tionality seems to be compromised at the signal trans-
duction level, as evidenced by the decrease in basal and
FK-stimulated AC activity as well as in the inhibitory
effect of SRIF on these activities. In addition, Ab(25–
35) induces a decrease in SRIF-LI content in the rat
hippocampus. Hence, these ﬁndings seem to implicate
Ab in the impairment of somatostatinergic transmission
that occurs in AD. Because chronic i.c.v. infusion of
Ab(25–35) impairs learning and memory whereas SRIF
facilitates these functions, the alterations described in the
present study might be correlated with the decreased
cognitive behavior previously reported for Ab-treated rats.
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